- The trend backdrop is active with a 14-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
AMANTA
NSI
Week ended 07 Aug 2026
Weekly Investor Report
AMANTA HEALTHCARE LIMITED · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
166.1 INR
-1.5%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 29.0% above the Trend Line and sits at 76.4% of its 52-week range. The latest completed week returned -1.5%, after a -7.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal.
Setup score
56
out of 100
Latest Close
166.1 INR
7 Aug 2026
1W Return
-1.5%
latest completed week
4W Return
-7.3%
short-term follow-through
12W Return
28.4%
quarterly tape
Trend Breadth
29.2%
14 of 48 weeks active
Volume Ratio
0.3x
vs 13-week average
- 3 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.5%
Latest completed week; four-week move -7.3%.
Indicator stack
61/76
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 67.51%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
53/100
52 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 29.0% above the Trend Line and sits at 76.4% of its 52-week range. The latest completed week returned -1.5%, after a -7.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.8512-week average 0.73
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.85Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers
No recent accumulation markers. 3 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -7.3% over four weeks, 28.4% over 12 weeks, and - over one year. The current trend has remained active for 14 consecutive weeks.
Performance by holding period
Active trend streak14 weeks
Active weeks in one year14
Trend breadth29.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.51Latest activity-pressure read.
Pressure change-14.4%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 88%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality73/100Profitability and accounting quality. Underlying universe rank 28; rank 1 is best.
Momentum44/100Medium-term price momentum. Underlying universe rank 57; rank 1 is best.
Growth63/100Revenue and earnings growth. Underlying universe rank 38; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework57/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 37.2x Price divided by trailing earnings.
- Price / sales
- 2.2x Market value relative to trailing revenue.
- EV / EBITDA
- 12.7x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.9% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 65.0% Gross profit retained from each unit of revenue.
- Operating margin
- 15.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -10.8% Free cash flow generated from revenue.
- Return on invested capital
- 8.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 4.7% Latest one-year revenue growth.
- EPS growth
- 41.7% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -222.8% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.1% Cash dividends relative to market value.
- Buyback yield
- -17.8% Net share repurchases relative to market value.
- Shareholder yield
- -17.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment53/100
Weighted news tone is neutral across 52 relevant articles.
10 positive · 40 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-12.1%Distance below the 52-week high.
13-week volatility5.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher17 of 269 weeks finished lower.
Best week+15.7%Week of 17 Apr.
Worst week-6.7%Week of 15 May.
Latest week-1.5%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains11
Flat weeks0
Modest losses6
Sharp losses3
Recent vol5.8%13-week weekly-return volatility.
Base vol5.1%52-week weekly-return volatility.
Up/down split25/22Count of positive and negative weeks in the 52-week window.
Average skew4.1% / -3.6%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank78 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape57/100
Trend, activity pressure, participation, and risk combine to a 57/100 tape read.
Indicator analysis64/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 0/12.
Activity pressure 0.85; 3 reversal markers Next-Week ExpectancyPositive 67.51%Next-week expectancy is positive with a 67.51% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors65/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 97; Small Cap Core rank 63 SVQF57/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 678.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment53/100Weighted news tone is neutral across 52 relevant articles.
GE HealthCare’s (NASDAQ:GEHC) Q2 CY2026: Beats On Revenue, Stock Soars Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 166.1 INR | -1.5% | 128.8 INR | 125.8 INR | 1.51 | - | 102.2K | On |
| 31 Jul 2026 | 168.7 INR | 3.5% | 126.9 INR | 124.9 INR | 1.71 | - | 149.5K | On |
| 24 Jul 2026 | 163.0 INR | -3.0% | 125.0 INR | 124.0 INR | 1.76 | - | 166.6K | On |
| 17 Jul 2026 | 168.0 INR | -6.2% | 123.1 INR | 123.1 INR | 1.79 | - | 178.9K | On |
| 10 Jul 2026 | 179.2 INR | 9.9% | 121.2 INR | 122.1 INR | 1.76 | - | 775.0K | On |
| 3 Jul 2026 | 163.1 INR | 1.5% | 118.8 INR | 120.7 INR | 1.64 | - | 187.0K | On |
| 26 Jun 2026 | 160.7 INR | 2.7% | 116.8 INR | 119.7 INR | 1.40 | - | 0 | On |
| 19 Jun 2026 | 156.4 INR | 3.0% | 114.9 INR | 118.7 INR | 1.21 | - | 123.7K | On |
| 12 Jun 2026 | 151.8 INR | 13.7% | 113.6 INR | 117.8 INR | 1.09 | - | 778.9K | On |
| 5 Jun 2026 | 133.5 INR | 6.4% | 112.6 INR | 116.9 INR | 1.02 | - | 105.3K | On |
| 29 May 2026 | 125.5 INR | -3.5% | 112.2 INR | 116.5 INR | 1.20 | - | 542.4K | On |
| 22 May 2026 | 130.1 INR | 0.5% | 112.1 INR | 116.2 INR | 1.38 | - | 385.8K | On |
| 15 May 2026 | 129.4 INR | -6.7% | 111.9 INR | 115.9 INR | 1.59 | - | 667.3K | On |
| 8 May 2026 | 138.8 INR | 5.8% | 111.7 INR | 115.5 INR | 1.75 | - | 563.9K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.